Moderna stock jumps as ESMO cancer data and FDA vaccine approvals fuel rally

Published on 09/21/2026 at 22:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock surged more than 13 percent on September 21, 2026 as investors cheered late?breaking cancer data accepted for ESMO 2026 and fresh FDA approvals for updated COVID?19 vaccines. The shares traded near their 52?week high above USD 176 with market cap around USD 70.4 billion.

Moderna Inc., US60770K1079, Illustration mit AI erstellt.

Moderna, Inc. stock (ISIN US60770K1079) is rallying sharply, with the Nasdaq-listed shares trading around USD 176 on September 21, 2026 after late?breaking Phase 3 cancer vaccine data were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 and regulators cleared the company’s updated 2026–2027 COVID?19 vaccines.

Cancer vaccine data drives Moderna stock higher

According to Barchart on September 21, 2026, Moderna announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted as late?breaking presentations at ESMO Congress 2026, which runs October 23–27, 2026 in Madrid, Spain.

As Yahoo Finance reports, the Phase 3 adjuvant melanoma study for intismeran autogene was selected for a prestigious Presidential Symposium slot at ESMO, a program slot organizers reserve for datasets seen as potentially practice?changing in oncology.

Investing.com notes that Moderna stock surged about 9.3 percent in morning trading on September 21, 2026, reaching roughly USD 168.36 as investors reacted to what many analysts describe as a once?in?a?generation clinical milestone for personalized neoantigen vaccines and mRNA-based cancer therapy, pushing the shares toward a 52?week high of USD 176.66.Investing.com

Stock near 52-week high on strong momentum

Moderna shares have moved into new territory, with the stock setting a fresh 12?month high during trading on September 21, 2026; MarketBeat cites an intraday high of USD 176.86 and a last trade around USD 174.56, supported by volume of more than 16.2 million shares.MarketBeat

In a separate update, Investing.com highlights that Moderna stock hit a 52?week high at USD 176.75 on September 21, 2026 and was trading around USD 176.21 that afternoon, giving the company a market capitalization of about USD 70.4 billion and reflecting a remarkable 556.4 percent share-price increase over the past year.Investing.com

Price action has been particularly intense in late August and September: StocksToTrade reports that Moderna stock climbed from roughly USD 134.10 on August 31, 2026 to about USD 174.48 on September 21, 2026, a gain of around 30 percent over that period as breakthrough oncology and vaccine catalysts drew in momentum traders.StocksToTrade

Analyst reaction and valuation debate

The powerful move in Moderna stock has triggered renewed analyst activity. According to Investing.com, Argus upgraded Moderna to Buy with a price target of USD 180 in response to the Phase 3 melanoma data and the FDA approvals of updated COVID?19 vaccines.Investing.com

The same Investing.com report notes that Wolfe Research upgraded Moderna to Peerperform following promising intismeran platform results, with the house pointing to potential peak sales of about USD 9.2 billion across multiple oncology indications if the data translate into broad approvals across high?risk melanoma and other cancers.

Not all analysts are uniformly positive: Investing.com cites Rothschild Redburn’s downgrade of Moderna to Sell in early September 2026 on valuation concerns, even as the firm acknowledged the strength of the Phase 3 melanoma results with Merck’s Keytruda combination and improved recurrence?free survival in high?risk patients.Investing.com

COVID-19 vaccines support revenue base

Beyond oncology, Moderna still depends on its respiratory vaccine franchise. StocksToTrade reports that regulators approved Moderna’s updated 2026–2027 Spikevax and mNEXSPIKE COVID?19 vaccines targeting the JN.1-lineage XFG variant, reinforcing recurring COVID?19 revenue ahead of the 2026–2027 respiratory season.StocksToTrade

StockStory adds that the FDA approvals for updated COVID?19 vaccines, combined with the Phase 3 INTerpath-001 melanoma trial results and late?breaking ESMO data, have improved regulatory sentiment around Moderna’s portfolio and helped underpin the stock’s recent strength.StockStory

However, TradingKey notes that even with these catalysts, Moderna reported annual revenue of about USD 1.94 billion and a net loss of roughly USD 2.82 billion in its most recent fiscal year, underlining that the company is still in an investment phase and depends on future commercialization of oncology and other pipeline assets to achieve sustainable profitability.TradingKey

Balance sheet and funding for development

StockStory highlights that Moderna completed a USD 2.6 billion convertible note offering in late August 2026 to provide dedicated funding for ongoing oncology development, including late?stage studies for intismeran autogene and other mRNA-based cancer therapies.StockStory

For investors, this combination of a sizable net loss of USD 2.82 billion and a large, USD 2.6 billion convertible note financing underscores both the capital intensity of Moderna’s oncology push and the degree to which success or failure of the intismeran program could reshape the company’s long?term earnings and balance sheet profile.

Moderna stock price and market snapshot

As of September 21, 2026, Moderna stock is trading on the Nasdaq around USD 176, very close to its 52?week high of USD 176.75, with intraday moves of more than 13 percent and a market capitalization in the area of USD 70.4 billion, underscoring the scale of the recent re?rating.